Cochrane review highlights systemic gaps in Alzheimer’s amyloid-focused treatment strategies
Original framing: “STAT+: Cochrane review reignites Alzheimer’s amyloid wars” — STAT News
The Cochrane review provides a meta-analysis of clinical trials, revealing that amyloid-targeting therapies have not consistently improved cognitive outcomes. This calls into question the scientific validity of the amyloid hypothesis as a primary treatment target.
The Cochrane review on Alzheimer’s amyloid-targeting therapies reveals a systemic overreliance on a single-biomarker model that has dominated research for decades.
This framing, reinforced by media and industry interests, obscures the role of inflammation, lifestyle, and environmental factors in cognitive decline. Cross-culturally, alternative models from indigenous and holistic health systems offer a more integrative approach to brain health. Future research must move beyond the amyloid hypothesis and incorporate diverse perspectives, including those of marginalized communities, to develop more effective and equitable solutions. This requires not only scientific innovation but also a reimagining of regulatory and funding structures to support multifactorial, patient-centered care.